Early application of CARVYKTI® has shown the potential for prolonged remission periods without ongoing treatment, even as early as 2.5 years in patients battling relapsed or refractory multiple myeloma. But here's where it gets controversial... new follow-up data from the CARTITUDE-4 trial indicate that over 80% of standard-risk patients, who received CARVYKTI® as early as first relapse and underwent just a single infusion, remained free from disease progression and did not require additional treatment at the 2.5-year mark. This finding hints at the possibility that administering CARVYKTI® earlier in the treatment sequence might lead to more durable results.
The latest results, supported by data from over 9,000 patients treated worldwide with CARVYKTI®, underscore this potential shift in treatment strategy. Specifically, analyses have shown that patients who received CARVYKTI® earlier—meaning after fewer prior treatments—demonstrated enhanced immune system health. This improved immune fitness appears to correlate with longer periods during which the disease does not worsen, known as progression-free survival (PFS). These insights were detailed during oral presentations at the 2025 American Society of Hematology (ASH) Annual Meeting, emphasizing the significance of treating patients sooner rather than later.
Luciano J. Costa, M.D., Ph.D., a leading researcher and professor at the University of Alabama, stated, “The data suggest that a single infusion of CARVYKTI® in standard-risk patients might offer additional benefits when used as early as the second line of therapy.” He further explained that addressing multiple myeloma after the first relapse can lead to deeper, longer-lasting responses, bringing us closer to a future where long-term remission—and possibly cure—is achievable.
Jordan Schecter, M.D., Vice President of Research & Development for Multiple Myeloma at Johnson & Johnson, added, “Our aim is to intervene as early as possible when the patient’s chances for lasting remission are highest. With over 9,000 patients treated globally, CARVYKTI® has already demonstrated remarkable effectiveness when used at first relapse. It’s the first and only CAR-T therapy proven to significantly extend overall survival compared to standard treatments.”
Looking into the specifics of the CARTITUDE-4 data, 176 patients received CARVYKTI® starting at the second line of treatment, with 59 of these having standard-risk cytogenetics—a favorable genetic profile. With an average follow-up of approximately 33.6 months, the data reveal that 80.5% of these patients remained free from disease progression at 30 months after a single dose. Strikingly, all 26 patients who achieved minimal residual disease (MRD)-negative complete responses—meaning no detectable cancer at a very sensitive level—at 12 months continued to be progression-free 30 months later.
Further analyses explored immune markers that might explain these outcomes. Patients treated earlier in their treatment journey exhibited a stronger immune profile characterized by higher levels of naive CD4+ T cells, immune cells crucial for fighting disease. Bone marrow studies corroborated this, showing that earlier treatment was associated with a more active immune environment, which is believed to contribute to longer PFS. These immunologic factors may hold the key to understanding why earlier intervention leads to better survival results.
As CARVYKTI® becomes more widely available across different healthcare settings—both academic and community-based—Johnson & Johnson continues to gather real-world data. This ongoing collection aims to better understand its long-term benefits and safety, supporting a potential expansion into even earlier treatment stages.
**To give context, the landmark CARTITUDE-1 trial was instrumental in establishing CARVYKTI® as a highly effective CAR-T therapy for heavily pretreated patients. It involved 99% of participants who were resistant to their last therapy and 88% with multiple-drug resistant disease. The initial goals were to evaluate safety and determine the appropriate dose. The promising efficacy results from this study led to FDA approval in February 2022 for patients who had undergone four or more prior lines of therapy, including standard agents. Most recently, in April 2024, CARVYKTI® gained approval as the first and only cell therapy indicated for patients with relapsed or refractory multiple myeloma who have received at least one prior treatment—including those resistant to lenalidomide, a key medication in this setting.
CARVYKTI® functions by reprogramming a patient's own T-cells to target BCMA—a protein found predominantly on malignant plasma cells in multiple myeloma. The therapy involves the genetic modification of the patient’s T-cells to carry a receptor that recognizes and kills cancerous cells expressing BCMA, thereby harnessing the immune system’s power. Developed through an exclusive partnership between Johnson & Johnson and Legend Biotech, this innovative therapy represents a significant advancement in personalized cancer treatment.
**And here’s the most compelling part—while current therapies for multiple myeloma are effective, this disease remains incurable, and resistance often develops. The emergence of CARVYKTI® and similar immunotherapies offers hope for longer remissions and improved survival. But some might ask—should we really be administering advanced therapies like CARVYKTI® earlier in the disease course? Or does doing so pose additional risks? The data are promising, but the conversation is just beginning. What do you think—should early intervention become the new standard, or are there hidden pitfalls? Share your thoughts below and join the debate on whether shifting treatment earlier is truly the best way forward for patients with multiple myeloma.
